论文部分内容阅读
目的观察和评价含氯法齐明方案治疗耐多药肺结核近期(治疗前6个月)效果。方法 66例耐多药肺结核患者,随机分为对照组和治疗组,各33例。对照组患者采用6个月吡嗪酰胺、阿米卡星、左氯氟沙星、丙硫异烟胺/18个月吡嗪酰胺、左氯沙星、丙硫异烟胺治疗方案;治疗组患者采用6个月吡嗪酰胺、阿米卡星、左氯氟沙星、丙硫异烟胺、氯法齐明/18个月吡嗪酰胺、左氧氟沙星、丙硫异烟胺、氯法齐明治疗方案。比较两组治疗效果。结果治疗组和对照组在治疗第6个月末痰菌阴转率分别为57.8%、30.3%,两组比较差异有统计学意义(P<0.05);治疗组和对照组在治疗第6个月末肺部CT改变有效例数分别为26、16例,有效率分别为78.8%、51.5%,两组比较差异有统计学意义(P<0.05)。结论含氯法齐明方案治疗耐多药肺结核近期疗效显著,临床可积极实践。
Objective To observe and evaluate the effect of chlorfluazapine in the treatment of MDR-TB (6 months before treatment). Methods Sixty-six patients with MDR-TB were randomly divided into control group and treatment group, with 33 cases in each group. Patients in the control group were treated with pyrazinamide, amikacin, levofloxacin, prothionamide / 18-month pyrazinamide, levofloxacin, and prothiamine for 6 months. The treatment group Patients were treated with pyrazinamide, amikacin, levofloxacin, prothionamide, clofazimine for 18 months, pyrazinamide for 18 months, levofloxacin, prothionamide, clofazimine Treatment programs. Compare the treatment effect of two groups. Results The sputum negative conversion rates of the treatment group and the control group at the end of the sixth month of treatment were 57.8% and 30.3%, respectively, with significant difference between the two groups (P <0.05). The treatment group and the control group had no significant difference in the sixth month The effective number of pulmonary CT changes were 26,16 cases, the effective rates were 78.8%, 51.5%, the difference between the two groups was statistically significant (P <0.05). Conclusion Clofazimim solution for the treatment of multidrug-resistant pulmonary tuberculosis recent significant effect, the clinical practice can be positive.